Dabigatran Reversal Agent – Idarucizumab
Thanks to Rob MacSweeney‘s fantastic Critical Care Reviews I learned of Idarucizumab, a monoclonal antibody fragment that binds the (pesky) […]
Thanks to Rob MacSweeney‘s fantastic Critical Care Reviews I learned of Idarucizumab, a monoclonal antibody fragment that binds the (pesky) […]
The group usually considered the universal donor for fresh frozen plasma because it contains no anti-A or anti-B antibodies is […]
Notes from Day 4 of the London Trauma Conference The highlight for me was Mr Jonny Morrison speaking on Resuscitative […]
Image: Red blood cells infected with malaria, public domain, via Wikimedia Commons The AABB (formerly the American Association of Blood […]
The prevention and management of venous thromboembolic disease is a huge topic, which generates questions for emergency, critical care, and […]
Pharmaceutical company Eli Lilly has announced the withdrawal of its severe sepsis drug activated protein C, or drotrecogin alfa (proprietary […]
A small study on normal volunteers examined reversal of the new oral anticoagulants, Rivaroxaban and Dabigatran. Rivaroxaban is a Factor […]
Acute traumatic coagulopathy (ATC) is present in up to 25% of major trauma patients by the time they arrive in […]
The overall effect of the antifibrinolytic drug tranexamic acid on outcome from major trauma was assessed in the CRASH-2 trial, […]
Replacement of clotting factors in bleeding trauma patients seems to be of benefit, but are coagulation factor concentrates safer than […]